A011-14 A Phase 3 Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality

NCT04896008

A Phase 3 Study of Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality

Associated Conditions

Pulmonary Hypertension

Principal Investigator

Melisa Wilson

Sponsor

Acceleron Pharma

Pulmonary arterial hypertension (PAH) is a disease affecting the blood vessels of the lungs. PAH leads to increased pressure in the blood vessels of the lungs which further leads to straining of the right side of the heart.

This study is currently enrolling.